Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Regan, Meredith M × Neven, Patrick Giobbie-Hurder, Anita Goldhirsch, Aron Ejlertsen, Bent Mauriac, Louis Forbes, John F Smith, Ian Láng, István Wardley, Andrew Rabaglio, Manuela Price, Karen N Gelber, Richard D Coates, Alan S Thürlimann, Beat BIG 1-98 Collaborative Group International Breast Cancer Study Group (IBCSG) #
Lancet Pub. Group
The Lancet Oncology vol:12 issue:12 pages:1101-8
Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up.